- Home
- FOF vs CERS Comparison
FOF vs CERS Comparison
Compare FOF & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- CERS
- Stock Information
- Founded
- FOF 2006
- CERS 1991
- Country
- FOF United States
- CERS United States
- Employees
- FOF N/A
- CERS N/A
- Industry
- FOF Investment Managers
- CERS EDP Services
- Sector
- FOF Finance
- CERS Technology
- Exchange
- FOF Nasdaq
- CERS Nasdaq
- Market Cap
- FOF 342.8M
- CERS 347.3M
- IPO Year
- FOF N/A
- CERS 1997
- Fundamental
- Price
- FOF $12.51
- CERS $1.65
- Analyst Decision
- FOF
- CERS Buy
- Analyst Count
- FOF 0
- CERS 3
- Target Price
- FOF N/A
- CERS $3.17
- AVG Volume (30 Days)
- FOF 58.7K
- CERS 1.6M
- Earning Date
- FOF 01-01-0001
- CERS 02-20-2025
- Dividend Yield
- FOF 9.07%
- CERS N/A
- EPS Growth
- FOF N/A
- CERS N/A
- EPS
- FOF N/A
- CERS N/A
- Revenue
- FOF N/A
- CERS $180,270,000.00
- Revenue This Year
- FOF N/A
- CERS $15.95
- Revenue Next Year
- FOF N/A
- CERS $10.50
- P/E Ratio
- FOF N/A
- CERS N/A
- Revenue Growth
- FOF N/A
- CERS 15.29
- 52 Week Low
- FOF $9.59
- CERS $1.38
- 52 Week High
- FOF $11.75
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- FOF 41.08
- CERS 41.40
- Support Level
- FOF $12.48
- CERS $1.64
- Resistance Level
- FOF $12.70
- CERS $1.96
- Average True Range (ATR)
- FOF 0.15
- CERS 0.11
- MACD
- FOF 0.00
- CERS -0.02
- Stochastic Oscillator
- FOF 25.00
- CERS 3.12
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.